These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 17389619)

  • 1. Rituximab: effective treatment for severe steroid-dependent minimal change nephrotic syndrome?
    Hofstra JM; Deegens JK; Wetzels JF
    Nephrol Dial Transplant; 2007 Jul; 22(7):2100-2. PubMed ID: 17389619
    [No Abstract]   [Full Text] [Related]  

  • 2. Rapid remission of steroid and mycophenolate mofetil (mmf)-resistant minimal change nephrotic syndrome after rituximab therapy.
    Yang T; Nast CC; Vo A; Jordan SC
    Nephrol Dial Transplant; 2008 Jan; 23(1):377-80. PubMed ID: 17981884
    [No Abstract]   [Full Text] [Related]  

  • 3. Unexpected efficacy of rituximab in multirelapsing minimal change nephrotic syndrome in the adult: first case report and pathophysiological considerations.
    François H; Daugas E; Bensman A; Ronco P
    Am J Kidney Dis; 2007 Jan; 49(1):158-61. PubMed ID: 17185157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Six refractory lupus patients treated with rituximab: a case series.
    Gillis JZ; Dall'era M; Gross A; Yazdany J; Davis J
    Arthritis Rheum; 2007 Apr; 57(3):538-42. PubMed ID: 17394185
    [No Abstract]   [Full Text] [Related]  

  • 5. Some of the people all of the time, all of the people none of the time.
    Bomback AS
    Am J Kidney Dis; 2009 Dec; 54(6):xxxiii-xxxiv. PubMed ID: 19932872
    [No Abstract]   [Full Text] [Related]  

  • 6. Schnitzler syndrome: treatment failure to rituximab but response to anakinra.
    Eiling E; Möller M; Kreiselmaier I; Brasch J; Schwarz T
    J Am Acad Dermatol; 2007 Aug; 57(2):361-4. PubMed ID: 17467852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab therapy for steroid-dependent minimal change nephrotic syndrome.
    Gilbert RD; Hulse E; Rigden S
    Pediatr Nephrol; 2006 Nov; 21(11):1698-700. PubMed ID: 16932900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A case of minimal change disease evolving into steroid-dependent nephrotic syndrome with hematuria.
    Jonkers IJ; Bruijn JA; Vleming LJ
    Am J Kidney Dis; 2004 Oct; 44(4):773-7. PubMed ID: 15384031
    [No Abstract]   [Full Text] [Related]  

  • 9. Rituximab-responsive nephrotic syndrome due to minimal change disease in systemic lupus erythematosus.
    Shahane A; Khasnis A; Gota C
    J Clin Rheumatol; 2012 Jun; 18(4):199-202. PubMed ID: 22647855
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment failure with rituximab in a patient with pemphigus vulgaris.
    Weger W; Aberer E
    J Eur Acad Dermatol Venereol; 2008 Mar; 22(3):387-9. PubMed ID: 18269618
    [No Abstract]   [Full Text] [Related]  

  • 11. Rituximab in adult minimal change disease and focal segmental glomerulosclerosis.
    Kronbichler A; Bruchfeld A
    Nephron Clin Pract; 2014; 128(3-4):277-82. PubMed ID: 25401966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of single-dose rituximab on steroid-dependent minimal-change nephrotic syndrome in adults.
    Takei T; Itabashi M; Moriyama T; Kojima C; Shiohira S; Shimizu A; Tsuruta Y; Ochi A; Amemiya N; Mochizuki T; Uchida K; Tsuchiya K; Nitta K
    Nephrol Dial Transplant; 2013 May; 28(5):1225-32. PubMed ID: 23239834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease.
    Munyentwali H; Bouachi K; Audard V; Remy P; Lang P; Mojaat R; Deschênes G; Ronco PM; Plaisier EM; Dahan KY
    Kidney Int; 2013 Mar; 83(3):511-6. PubMed ID: 23325085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Lipoid nephrosis in childhood].
    Niaudet P
    Rev Prat; 2003 Nov; 53(18):2027-32. PubMed ID: 15008217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab for treatment of ocular inflammatory disease: a series of four cases.
    Kurz PA; Suhler EB; Choi D; Rosenbaum JT
    Br J Ophthalmol; 2009 Apr; 93(4):546-8. PubMed ID: 19321476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab as a Therapeutic Option for Steroid-Sensitive Minimal Change Nephrotic Syndrome in Adults.
    Iwabuchi Y; Moriyama T; Itabashi M; Takei T; Nitta K
    Contrib Nephrol; 2018; 195():12-19. PubMed ID: 29734146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beneficial effect of chlorambucil in steroid-dependent and cyclophosphamide-resistant minimal change nephrotic syndrome.
    Ueda N; Takahashi K; Akioka Y; Morooka M; Ogawa A; Tsuzuki K
    J Nephrol; 2009; 22(5):610-5. PubMed ID: 19809993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complete remission of lupus nephritis with rituximab and steroids for induction and rituximab alone for maintenance therapy.
    Camous L; Melander C; Vallet M; Squalli T; Knebelmann B; Noël LH; Fakhouri F
    Am J Kidney Dis; 2008 Aug; 52(2):346-52. PubMed ID: 18572292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adult minimal-change disease: clinical characteristics, treatment, and outcomes.
    Waldman M; Crew RJ; Valeri A; Busch J; Stokes B; Markowitz G; D'Agati V; Appel G
    Clin J Am Soc Nephrol; 2007 May; 2(3):445-53. PubMed ID: 17699450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab in minimal change nephropathy and focal segmental glomerulosclerosis: report of four cases and review of the literature.
    Peters HP; van de Kar NC; Wetzels JF
    Neth J Med; 2008 Nov; 66(10):408-15. PubMed ID: 19011266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.